Veeva beats earnings estimates, lifts FY27 guidance on AI momentum
Cloud software provider delivers 5.6% EPS beat and raises revenue outlook as AI agents gain traction
Veeva Systems shares climbed in after-hours trading Wednesday after the cloud software provider for the life sciences industry reported fourth-quarter earnings that beat analyst expectations and raised its guidance for fiscal year 2027, buoyed by growing adoption of its AI-powered tools.
The Pleasanton, California-based company reported adjusted earnings per share of $2.06 for the quarter ended January 31, surpassing the Wall Street consensus estimate of $1.95 by 5.6%. Revenue of $836 million exceeded expectations of $793 million, representing a 13% year-over-year increase and reaching the high end of the company's guidance range.
"Our performance in Q4 demonstrates the strength of our business and the significant opportunity ahead," said Peter Gassner, Veeva's chief executive officer. He highlighted what he termed the "agentic transformation" opportunity, noting that Veeva's AI agents are gaining traction with customers across the life sciences industry.
Veeva's profitability metrics showed robust expansion. Operating income increased 30% from the prior-year quarter, while net income rose 25%, underscoring the company's ability to scale efficiently even amid product transition efforts. The company's profit margin stands at 27.9%, with quarterly revenue growth of 16% year-over-year.
For the fiscal year ending January 31, 2027, Veeva raised its guidance to total revenue of $3.585 billion to $3.6 billion, up from previous projections. The company expects non-GAAP fully diluted earnings per share of approximately $8.85, compared to $8.10 in fiscal 2026. First-quarter revenue is projected between $855 million and $858 million, with EPS of $2.13 to $2.14.
The stronger-than-expected results provided reassurance to investors who have been watching Veeva navigate its Vault CRM transition cycle and growing competitive pressure from Salesforce. Some analysts, including at Stifel and Barclays, had lowered their price targets in late February while maintaining buy or overweight ratings, citing concerns about the CRM transition.
Following the earnings release, Veeva shares rose in extended trading, adding to a stock that had already gained 1.4% during regular trading hours. The company now commands a market capitalization of approximately $29.8 billion.
Analysts remain broadly positive on Veeva's prospects. The stock carries a consensus rating of "Moderate Buy" with an average price target of $300.50, according to MarketBeat, suggesting significant upside from the current price around $188. Of the 33 analysts covering the stock, 9 rate it a strong buy and 15 recommend buy, while 8 suggest hold and just one advocates selling.
Veeva's strong operating margins during the transition period reflect what some analysts describe as the company's ability to maintain efficiency while investing in new capabilities. The company's forward price-to-earnings ratio of 21.05 represents a premium to the market, reflecting investor expectations for continued growth.
Looking ahead, investors will be focused on several key catalysts, including the pace of Vault CRM adoption among pharmaceutical and biotechnology customers, the competitive landscape against larger rivals like Salesforce, and the commercial success of Veeva's AI agent offerings. The life sciences industry remains a sticky customer base with high switching costs, providing Veeva with some insulation from broader economic volatility.
Veeva has a history of exceeding Wall Street expectations, and Wednesday's results mark another quarter of outperformance. However, the company faces pressure to demonstrate that its AI initiatives can translate into meaningful revenue acceleration while maintaining the high-margin profile that has made it a favorite among growth investors.